Cargando…

Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies

SIMPLE SUMMARY: Immune checkpoint blockade has provided durable clinical responses in a number of human malignancies, but not in patients with pancreatic cancer. Efforts to understand mechanisms of resistance and increase efficacy of immune checkpoint blockade in pancreatic cancer require the use of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pham, Thao N. D., Shields, Mario A., Spaulding, Christina, Principe, Daniel R., Li, Bo, Underwood, Patrick W., Trevino, Jose G., Bentrem, David J., Munshi, Hidayatullah G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865443/ https://www.ncbi.nlm.nih.gov/pubmed/33503832 http://dx.doi.org/10.3390/cancers13030440

Ejemplares similares

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
por: Principe, Daniel R., et al.
Publicado: (2021)

Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8(+) T cell antitumor immunity
por: Pham, Thao N.D., et al.
Publicado: (2022)

Quercetin Enhances the Anti-Tumor Effects of BET Inhibitors by Suppressing hnRNPA1
por: Pham, Thao N.D., et al.
Publicado: (2019)

BET inhibition rescues ciliogenesis and ameliorates pancreatitis-driven phenotypic changes in mice with Par3 loss
por: Shields, Mario A., et al.
Publicado: (2023)

Contribution of Epithelial-Mesenchymal Transition to Pancreatic Cancer Progression
por: Krantz, Seth B., et al.
Publicado: (2010)

Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin
por: Shields, Mario A., et al.
Publicado: (2022)

Controlling TIME: How MNK Kinases Function to Shape Tumor Immunity
por: Pham, Thao N.D., et al.
Publicado: (2020)

Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells
por: Ebine, Kazumi, et al.
Publicado: (2018)

Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
por: Principe, Daniel R., et al.
Publicado: (2022)

The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial
por: Metropulos, Anastasia E., et al.
Publicado: (2022)

Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer
por: Principe, Daniel R., et al.
Publicado: (2022)

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
por: Hoare, Owen, et al.
Publicado: (2021)

Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma
por: Underwood, Patrick W., et al.
Publicado: (2023)

Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models
por: Gündel, Beate, et al.
Publicado: (2021)

Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
por: Sarantis, Panagiotis, et al.
Publicado: (2020)

Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer
por: Kumar, Krishan, et al.
Publicado: (2023)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
por: Bailey, Peter, et al.
Publicado: (2016)

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020)

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
por: Fan, Jia-qiao, et al.
Publicado: (2020)

Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
por: Schmiechen, Zoe C., et al.
Publicado: (2021)

Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
por: Smith, Caitlyn, et al.
Publicado: (2022)

Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
por: Li, Yan, et al.
Publicado: (2022)

Slug inhibits pancreatic cancer initiation by blocking Kras-induced acinar-ductal metaplasia
por: Ebine, Kazumi, et al.
Publicado: (2016)

KRAS(G12D) and TP53(R167H) Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs
por: Principe, Daniel R., et al.
Publicado: (2018)

Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
por: Yu, Yiqi, et al.
Publicado: (2021)

XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer
por: Principe, Daniel R., et al.
Publicado: (2022)

Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy
por: Hou, Wanting, et al.
Publicado: (2022)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
por: Barat, Maxime, et al.
Publicado: (2021)

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
por: He, Mengni, et al.
Publicado: (2020)

DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives
por: Stoof, Jojanneke, et al.
Publicado: (2021)

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015)

Translocation of Oral Microbiota into the Pancreatic Ductal Adenocarcinoma Tumor Microenvironment
por: McKinley, Kelley N. L., et al.
Publicado: (2023)

Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
por: Riner, Andrea N., et al.
Publicado: (2020)

PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction
por: Principe, Daniel R., et al.
Publicado: (2016)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment
por: Elrakaybi, Asmaa, et al.
Publicado: (2022)

Molecular Characteristics of Pancreatic Ductal Adenocarcinoma
por: Ottenhof, Niki A., et al.
Publicado: (2011)

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
por: Steele, Colin W., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c0cfo0fjqegt6ohjfoaom5ce3q